Medication adherence and real-world factors of first line induction treatment selection in ANCA-associated vasculitis.

Pınar Akyüz Dağlı, Esra Kayacan Erdoğan, Hatice Ecem Konak, Bahar Özdemir Ulusoy, Serdar Can Güven, Berkan Armağan, Rezan Koçak Ulucaköy, Kevser Orhan, Ebru Atalar, İsmail Doğan, Yüksel Maraş, Ahmet Omma, Orhan Küçükşahin, Şükran Erten, Hakan Babaoğlu
{"title":"Medication adherence and real-world factors of first line induction treatment selection in ANCA-associated vasculitis.","authors":"Pınar Akyüz Dağlı, Esra Kayacan Erdoğan, Hatice Ecem Konak, Bahar Özdemir Ulusoy, Serdar Can Güven, Berkan Armağan, Rezan Koçak Ulucaköy, Kevser Orhan, Ebru Atalar, İsmail Doğan, Yüksel Maraş, Ahmet Omma, Orhan Küçükşahin, Şükran Erten, Hakan Babaoğlu","doi":"10.36141/svdld.v42i3.16880","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & objective: </strong>This study aimed to explore real-world factors that may influence the selection of first-line remission-induction therapy in ANCA-associated vasculitis(AAV), as well as to evaluate physician compliance with guideline recommendations and patient adherence to maintenance therapies.</p><p><strong>Methods: </strong> A retrospective analysis of 112 patients with AAV, including granulomatosis with polyangiitis(GPA, 67%), microscopic polyangiitis(MPA, 13%),and eosinophilic granulomatosis with polyangiitis (EGPA, 20%), was conducted at a single tertiary care center using electronic health records from 2018 to 2023. Treatment regimens, patient demographics, organ involvement, and adherence to EULAR guidelines were analyzed.Patients receiving RTX or CYC as first-line remission-induction therapy were compared.Compliance was defined as alignment with guideline-recommended dosing and timing of induction therapy, while adherence during maintenance was evaluated based on consistency with prescribed regimens, assessed via prescription refill data.</p><p><strong>Results: </strong>Of the 102 patients included in the study, 85 received CYC and 17 received RTX as first-line remission induction therapy.Compared to the RTX group, those receiving CYC were significantly older (median age 57 vs. 44 years, p <0.05), had higher BVAS scores (median 12 vs. 10, p = 0.02), and exhibited more comorbidities (74% vs. 35%). Organ involvement rates were similar in both groups. No significant differences in major organ involvement were observed between the two groups. RTX adherence was 100% in both the induction and maintenance phases, whereas adherence to oral maintenance therapies was notably lower, at 66% for methotrexate, 36% for mycophenolate mofetil, and 28% for azathioprine.</p><p><strong>Conclusion: </strong>In real-world practice, older age, higher BVAS, and a greater comorbidity burden appear to influence clinicians' preference for CYC over RTX as first-line induction,despite similar organ involvement between groups.Overall compliance with induction guidelines was high,but adherence to oral maintenance regimens remained suboptimal.These findings underscore the need for personalized treatment strategies and targeted measures to enhance long-term medication adherence in AAV.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"42 3","pages":"16880"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536833/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36141/svdld.v42i3.16880","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background & objective: This study aimed to explore real-world factors that may influence the selection of first-line remission-induction therapy in ANCA-associated vasculitis(AAV), as well as to evaluate physician compliance with guideline recommendations and patient adherence to maintenance therapies.

Methods:  A retrospective analysis of 112 patients with AAV, including granulomatosis with polyangiitis(GPA, 67%), microscopic polyangiitis(MPA, 13%),and eosinophilic granulomatosis with polyangiitis (EGPA, 20%), was conducted at a single tertiary care center using electronic health records from 2018 to 2023. Treatment regimens, patient demographics, organ involvement, and adherence to EULAR guidelines were analyzed.Patients receiving RTX or CYC as first-line remission-induction therapy were compared.Compliance was defined as alignment with guideline-recommended dosing and timing of induction therapy, while adherence during maintenance was evaluated based on consistency with prescribed regimens, assessed via prescription refill data.

Results: Of the 102 patients included in the study, 85 received CYC and 17 received RTX as first-line remission induction therapy.Compared to the RTX group, those receiving CYC were significantly older (median age 57 vs. 44 years, p <0.05), had higher BVAS scores (median 12 vs. 10, p = 0.02), and exhibited more comorbidities (74% vs. 35%). Organ involvement rates were similar in both groups. No significant differences in major organ involvement were observed between the two groups. RTX adherence was 100% in both the induction and maintenance phases, whereas adherence to oral maintenance therapies was notably lower, at 66% for methotrexate, 36% for mycophenolate mofetil, and 28% for azathioprine.

Conclusion: In real-world practice, older age, higher BVAS, and a greater comorbidity burden appear to influence clinicians' preference for CYC over RTX as first-line induction,despite similar organ involvement between groups.Overall compliance with induction guidelines was high,but adherence to oral maintenance regimens remained suboptimal.These findings underscore the need for personalized treatment strategies and targeted measures to enhance long-term medication adherence in AAV.

anca相关性血管炎一线诱导治疗选择的药物依从性和现实因素。
背景与目的:本研究旨在探讨可能影响anca相关性血管炎(AAV)一线缓解诱导治疗选择的现实因素,并评估医生对指南建议的依从性和患者对维持治疗的依从性。方法:回顾性分析2018年至2023年在单一三级保健中心使用电子健康记录的112例AAV患者,包括肉芽肿病合并多血管炎(GPA, 67%)、显微镜下多血管炎(MPA, 13%)和嗜酸性肉芽肿病合并多血管炎(EGPA, 20%)。分析了治疗方案、患者人口统计、器官受累情况和对EULAR指南的遵守情况。比较接受RTX或CYC作为一线缓解诱导治疗的患者。依从性被定义为与指南推荐的剂量和诱导治疗的时间一致,而维持期间的依从性是基于与处方方案的一致性来评估的,通过处方补充数据来评估。结果:纳入研究的102例患者中,85例接受CYC治疗,17例接受RTX作为一线缓解诱导治疗。与RTX组相比,接受CYC的患者明显更老(中位年龄57岁vs. 44岁)。结论:在现实世界中,尽管两组之间器官受累相似,但年龄越大,BVAS越高,合病负担越大,似乎会影响临床医生对CYC而不是RTX作为一线诱导的偏好。诱导指南的总体依从性很高,但口服维持方案的依从性仍然不理想。这些发现强调需要个性化的治疗策略和有针对性的措施来提高AAV的长期药物依从性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书